News

Gene therapy to be authorised for first time in EU

BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e5009 (Published 23 July 2012) Cite this as: BMJ 2012;345:e5009
  1. Geoff Watts
  1. 1London

The European Medicines Agency has recommended that alipogene tiparvovec (marketed as Glybera) be authorised for sale in the European Union. Intended to treat lipoprotein lipase deficiency in patients with severe pancreatitis, it is the first gene therapy in Europe to be recommended for this status and is yet to be approved in the United States.

The deficiency is a genetic disorder thought to affect no more than one or two people in a million. The new treatment relies on an adeno-associated virus to deliver functional copies of the lipoprotein lipase gene to the body’s muscle cells.

“It’s fantastic news …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe